You just read:

RE-LY Sub-Analysis Suggests Pradaxa® (dabigatran etexilate mesylate) Associated with Similar Bleeding Rates and Thromboembolic Complications in Surgery Versus Warfarin

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Jun 18, 2012, 08:00 ET